Cargando…

COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis

The rapid transmission of the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), led to widespread infection throughout the world. Concerns and challenges regarding COVID-19 illness have emerged for patients with immune-m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deodhar, Atul, Bhana, Suleman, Winthrop, Kevin, Gensler, Lianne S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124289/ https://www.ncbi.nlm.nih.gov/pubmed/35598255 http://dx.doi.org/10.1007/s40744-022-00462-9

Ejemplares similares

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
por: Deodhar, Atul, et al.
Publicado: (2019)

Patient‐reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID‐19 Pandemic
por: Liew, Jean W., et al.
Publicado: (2020)

Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review
por: Mease, Philip, et al.
Publicado: (2022)

Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging
por: Maksymowych, Walter P, et al.
Publicado: (2022)

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Axial Spondyloarthritis in the Chiropractic Care Setting: A Systematic Literature Review
por: Deodhar, Atul, et al.
Publicado: (2022)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
por: Braun, Juergen, et al.
Publicado: (2023)

Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study
por: Robinson, Philip C., et al.
Publicado: (2022)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Human Leukocyte Antigen B27‐Negative Axial Spondyloarthritis: What Do We Know?
por: Deodhar, Atul, et al.
Publicado: (2023)

The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Coxitis in axial spondyloarthritis: the unmeasured, yet functionally most important, radiographic progression
por: Rocha, Francisco Airton Castro, et al.
Publicado: (2021)

COVID-19 vaccination and antirheumatic therapy
por: Arnold, Jack, et al.
Publicado: (2021)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
por: Braun, Jürgen, et al.
Publicado: (2021)

Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis: A Patient and Provider Survey in the United States
por: Deodhar, Atul, et al.
Publicado: (2020)

Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis
por: Liew, Jean W, et al.
Publicado: (2020)

Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2022)

Referral Patterns, Diagnosis, and Disease Management of Patients With Axial Spondyloarthritis: Results of an International Survey
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis
por: Rudwaleit, Martin, et al.
Publicado: (2023)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey
por: Hunter, Theresa, et al.
Publicado: (2021)

Effect of Biologics in Subgroups of Axial Spondyloarthritis Based on Magnetic Resonance Imaging and C‐Reactive Protein: A Systematic Review and Meta‐Analysis
por: Karmacharya, Paras, et al.
Publicado: (2023)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial
por: Deodhar, Atul, et al.
Publicado: (2020)

Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain
por: Deodhar, Atul, et al.
Publicado: (2016)

Minimal Impact of the COVID‐19 Pandemic on Disease Activity and Health‐Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open‐Label Extension Study
por: Robinson, Philip C., et al.
Publicado: (2022)

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
por: Landewé, Robert, et al.
Publicado: (2020)

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
por: Machado, Pedro M, et al.
Publicado: (2023)

Examining Treatment Decision‐Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey
por: Joo, Woojin, et al.
Publicado: (2020)

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Patient Burden of Axial Spondyloarthritis
por: Strand, Vibeke, et al.
Publicado: (2017)

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks
por: Deodhar, Atul, et al.
Publicado: (2021)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

The Genetics of Spondyloarthritis
por: Díaz-Peña, Roberto, et al.
Publicado: (2020)

Osteoimmunology of Spondyloarthritis
por: Fassio, Angelo, et al.
Publicado: (2023)

HLA-B27 is associated with reduced disease activity in axial spondyloarthritis
por: Rosenbaum, James T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h87ju607nds53hs0npev2fgp8r